BAY 60-2770_product_DataBase

Bioactivity	BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect[1][2].
In Vivo	BAY 60-2770 (0.1-0.3 mg/Kg; p.o.) attenuates liver fibrosis in two rat models[1].BAY 60-2770 (1 mg/kg; p.o.; daily from the 10th to the 12th week) results in amelioration of bladder dysfunction in high-fat obese mice[2]. Animal Model:
Name	BAY 60-2770
CAS	1027642-43-8
Formula	C35H33F4NO5
Molar Mass	623.63
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Reference	[1]. Knorr A, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung. 2008;58(2):71-80. [2]. Leiria LO, et al. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J Urol. 2014 Feb;191(2):539-47.

PeptideDB